Outcomes of Haploidentical Bone Marrow Transplantation in Infant Acute Leukemia: a Single Center Experience

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2024 Apr 9

PMID 38594510

Authors

Dimitrios Filioglou

Laurel Truscott

Naresh Reddivalla

Emmanuel Katsanis

Affiliations

Soon will be listed here.

References

Brown P, Pieters R, Biondi A . How I treat infant leukemia. Blood. 2018; 133(3):205-214. DOI: 10.1182/blood-2018-04-785980. View

Katsanis E, Sapp L, Reid S, Reddivalla N, Stea B . T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies. Front Pediatr. 2020; 8:282. PMC: 7295947. DOI: 10.3389/fped.2020.00282. View

Truscott L, Pariury H, Hanmod S, Davini M, De La Maza M, Sapp L . Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation. Pediatr Blood Cancer. 2022; 70(2):e30102. DOI: 10.1002/pbc.30102. View

Katsanis E, Stea B, Kovacs K, Truscott L, Husnain M, Khurana S . Feasibility and Efficacy of Partially Replacing Post-Transplantation Cyclophosphamide with Bendamustine in Pediatric and Young Adult Patients Undergoing Haploidentical Bone Marrow Transplantation. Transplant Cell Ther. 2022; 28(7):390.e1-390.e10. PMC: 9253073. DOI: 10.1016/j.jtct.2022.04.015. View

Katsanis E, Sapp L, Varner N, Koza S, Stea B, Zeng Y . Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2018; 24(10):2034-2039. PMC: 7556327. DOI: 10.1016/j.bbmt.2018.06.007. View

Kato M, Hasegawa D, Koh K, Kato K, Takita J, Inagaki J . Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for.... Br J Haematol. 2014; 168(4):564-70. DOI: 10.1111/bjh.13174. View

Ochoa-Fernandez B, Galan-Gomez V, Guerra-Garcia P, Sanroman S, Martinez I, Bueno D . Younger age and induction failure predict outcomes in infant leukemia: 30 years of experience in a tertiary center. Front Pediatr. 2023; 11:1166176. PMC: 10263122. DOI: 10.3389/fped.2023.1166176. View

Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle J . Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2017; 53(2):138-145. PMC: 5803572. DOI: 10.1038/bmt.2017.161. View

Philippe M, Neely M, Rushing T, Bertrand Y, Bleyzac N, Goutelle S . Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. Bone Marrow Transplant. 2018; 54(3):448-457. DOI: 10.1038/s41409-018-0281-7. View

10.

Bartelink I, Lalmohamed A, van Reij E, Dvorak C, Savic R, Zwaveling J . Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016; 3(11):e526-e536. PMC: 5159247. DOI: 10.1016/S2352-3026(16)30114-4. View

11.

Higham C, Collins G, Shimano K, Melton A, Kharbanda S, Winestone L . Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood Adv. 2021; 5(8):2106-2114. PMC: 8095147. DOI: 10.1182/bloodadvances.2020003988. View

12.

Jodele S, Dandoy C, Lane A, Laskin B, Teusink-Cross A, Myers K . Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020; 135(13):1049-1057. PMC: 7099329. DOI: 10.1182/blood.2019004218. View